8-K: Beyond Cancer Receives Israeli Approval for Phase 1b Trial of Nitric Oxide Therapy

Beyond Cancer, Ltd. has received approval from the Israeli Ministry of Health to begin a Phase 1b clinical trial of its Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) therapy in combination with anti-PD-1 therapy for solid tumor cancers.

Summary

• Beyond Cancer, Ltd., a majority-owned affiliate of Beyond Air, Inc., has been granted approval by the Israeli Ministry of Health to conduct a Phase 1b clinical trial.
• The trial will investigate the use of Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in combination with anti-PD-1 therapy.
• The study will focus on patients with unresectable cutaneous or subcutaneous solid tumors that have progressed or remained stable after anti-PD-1 treatment.
• The primary goal is to assess the preliminary efficacy of LV UNO by measuring the objective response rate (ORR) and duration of response (DOR).
• The trial will also evaluate immune-related responses and the safety and tolerability of the treatment.
• Up to 20 patients will be recruited across four sites in Israel, with patient screening expected to begin in the first quarter of 2025.
• Topline data from the Phase 1b study is anticipated in the second half of 2025.

Sentiment

Score: 7

Explanation: The document is positive due to the approval of the clinical trial, but there are still risks and uncertainties associated with the development of the therapy. The sentiment is cautiously optimistic.

Positives

• The approval from the Israeli Ministry of Health allows Beyond Cancer to advance its clinical development program.
• The combination therapy approach could offer a new treatment option for patients with anti-PD-1 resistant cancers.
• Preclinical studies have shown that UNO can increase PD-L1 expression and improve survival in animal models.
• Phase 1a human data has demonstrated immune system activation.
• The trial will assess both efficacy and safety of the LV UNO therapy.

Negatives

• The trial is still in an early phase (Phase 1b), and the results are not yet known.
• The study will only enroll a small number of patients (up to 20).
• The success of the therapy is not guaranteed, and there are risks associated with clinical trials.

Risks

• The trial results may not be positive, and the therapy may not be effective.
• Regulatory authorities may not approve the therapy even if the trial is successful.
• The company may face competition from other companies developing similar therapies.
• The company may need to raise additional capital to fund further development.
• There are risks associated with the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products.

Future Outlook

The company anticipates topline data from the Phase 1b trial in the second half of 2025 and views this trial as a major step forward in their vision for personalized cancer treatment. They see UNO as a complementary therapy for future cancer treatment paradigms, particularly for patients with anti-PD-1 refractory or resistant disease.

Management Comments

• Dr. Jedidiah Monson, Chief Medical Officer of Beyond Cancer, stated that they are excited to initiate the Phase 1b trial of LV UNO, a potentially groundbreaking solid tumor treatment approach, in combination with PD-1 inhibitors.
• Dr. Selena Chaisson, Chief Executive Officer, and Director of Beyond Cancer, stated that the initiation of the Phase 1b trial represents a major step forward in their vision for personalized cancer treatment and that they see UNO as a complementary therapy for future cancer treatment paradigms.

Industry Context

This announcement is relevant to the broader trend of developing novel immunotherapies for cancer, particularly those that can overcome resistance to existing treatments like anti-PD-1 inhibitors. The use of nitric oxide as an immunotherapeutic agent is an emerging area of research.

Comparison to Industry Standards

• The trial is a Phase 1b study, which is typical for early-stage clinical development of new cancer therapies.
• The use of objective response rate (ORR) and duration of response (DOR) as primary endpoints is standard in oncology clinical trials.
• The combination of a novel therapy (LV UNO) with an established treatment (anti-PD-1) is a common strategy in cancer drug development.
• Other companies such as Merck (Keytruda) and Bristol Myers Squibb (Opdivo) have developed anti-PD-1 therapies, and this trial is looking to improve on the results of these therapies.
• The trial is similar to other early-stage trials that are testing novel therapies in combination with anti-PD-1 inhibitors, such as those being conducted by companies like Iovance Biotherapeutics and Adaptimmune.

Stakeholder Impact

• Shareholders may react positively to the news of the clinical trial approval.
• Patients with solid tumors may benefit from the development of a new treatment option.
• Employees of Beyond Cancer may be motivated by the progress of the clinical program.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Patient screening will begin in the first quarter of 2025.
• The Phase 1b clinical trial will be conducted at four sites in Israel.
• Topline data from the trial is expected in the second half of 2025.

Key Dates

Keywords

Nitric Oxide, Cancer Therapy, Immunotherapy, Clinical Trial, Solid Tumors, Anti-PD-1, LV UNO, Beyond Cancer, Israeli Ministry of Health